The FDA says it won’t approve DBV Technologies’ Viaskin Peanut, the novel skin patch allergy desensitization treatment, at least not… Read more »
Peanut & Tree Nut
Palforzia OIT Study Sees Maturing of Immune System Over Time
A new study finds encouraging results for those considering the first FDA-approved peanut allergy immunotherapy. It reveals that clinical trial… Read more »
Groundbreaking Study Finds Peanut Allergy Likely Starts In The Gut
Groundbreaking Study Finds Peanut Allergy Likely Starts In The Gut
Allergists See Palforzia Starting New Era of Food Allergy Therapy
Allergists that Allergic Living contacted are excited about the FDA’s approval of the first-ever therapy for a food allergy. They… Read more »
Study Shows High Costs and Burden of Peanut Allergy
A study of a large U.S. health insurer database reveals the high dollar and health costs for those living with… Read more »
FDA Approves Aimmune’s Palforzia OIT, Coming Soon to Allergist Clinics
The Food and Drug Administration on Jan. 31, 2020 approved Palforzia, Aimmune Therapeutics’ oral immunotherapy (OIT) treatment for peanut allergy… Read more »
3 in 4 Kids See Benefit From Viaskin Peanut Patch After 3 Years
After three years of using the Viaskin Peanut patch in children ages 4 to 11, more than half (52 percent)… Read more »
FDA to Review Viaskin Peanut Patch for Possible Approval
DBV Technologies has announced that the FDA has agreed to review the company’s Viaskin Peanut patch for potential regulatory approval.… Read more »
Panel Backs FDA Approval for Aimmune’s Peanut OIT Drug
An expert advisory panel has recommended that the Food and Drug Administration approve Aimmune Therapeutics’ oral immunotherapy (OIT) treatment for… Read more »
Viaskin Peanut Patch Submitted to FDA for Approval Consideration
The manufacturer of the Viaskin Peanut patch has resubmitted its biologics license application (or BLA) to the FDA – in… Read more »